Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance

Molecular Cancer Research

Volumn 8, Issue 3, 2010, Pages 343-352

  Louie, Maggie C ^a,b   McClellan, Ashley ^a   Siewit, Christina ^b   Kawabata, Lauren ^a  

^a DOMINICAN UNIVERSITY OF CALIFORNIA   (United States)

^b TOURO UNIVERSITY CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN E; CYCLIN E1; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR SP 1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM;

BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; E2F1 TRANSCRIPTION FACTOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, CDC; HUMANS; IMMUNOGLOBULINS; PROMOTER REGIONS, GENETIC; S PHASE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 77949753453     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0395     Document Type: Article

References (42)

1. Kellen JA. Raloxifene: another selective estrogen modulator. In Vivo 2001;15:459-60.
2. Lewis JS, Jordan VC. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 2005;591:247-63.
3. Takimoto GS, Graham JD, Jackson TA, et al. Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors. J Steroid Biochem Mol Biol 1999;69:45-50.
4. Lavinsky RM, Jepsen K, Heinzel T, et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A 1998;95:2920-5.
5. Keeton EK, Brown M. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-á and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol Endocrinol 2005;19:1543-54.
6. Berglund P, Landberg G. Cyclin E overexpression reduces infiltrative growth in breast cancer: yet another link between proliferation control and tumor invasion. Cell Cycle 2006;5:606-9.
7. 1 cyclin-dependent kinases and cancers. Cancer Metastasis Rev 2003;22:435-49.
8. Musgrove EA. Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors 2006;24:13-9.
9. Sutherland RL, Musgrove EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 2004;9:95-104.
10. Louie MC, Revenko AS, Zou JX, Yao J, Chen HW. Direct control of cell cycle gene expression by proto-oncogene product ACTR, its autoregulation underlies its transforming activity. Mol Cell Biol 2006;26:3810-23.
11. Louie MC, Zou JX, Rabinovich A, Chen HW. ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol 2004;24:5157-71.
12. Li LB, Louie MC, Chen HW, Zou JX. Proto-oncogene ACTR/AIB1 promotes cancer cell invasion by up-regulating specific matrix metalloproteinase expression. Cancer Lett 2008;261:64-73.
13. Mussi P, Yu C, O'Malley BW, Xu J. Stimulation of steroid receptor coactivator-3 (SRC-3) gene overexpression by a positive regulatory loop of E2F1 and SRC-3. Mol Endocrinol 2006;20:3105-19.
14. Johnson DG, Ohtani K, Nevins JR. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev 1994;8:1514-25.
15. Wijayaratne AL, Nagel SC, Paige LA, Christensen DJ, Norris JD, Fowlkes DM, McDonnell DP. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 1999;140:5828-40.
16. Kilker RL, Hartl MW, Rutherford TM, Planas-Silva MD. Cyclin D1 expression is dependent on estrogen receptor function in tamoxifenresistant breast cancer cells. J Steroid Biochem Mol Biol 2004;92: 63-71.
17. Kim K, Thu N, Saville B, Safe S. Domains of estrogen receptor α (ERα) required for ERα/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells. Mol Endocrinol 2003;17:804-17.
18. Safe S, Kim K. Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J Mol Endocrinol 2008;41:263-75.
19. Bruning JC, Lingohr P, Gillette J, Hanstein B, Avci H, Krone W, Muller-Wieland D, Kotzka J. Estrogen receptor-á and Sp1 interact in the induction of the low density lipoprotein-receptor. J Steroid Biochem Mol Biol 2003;86:113-21.
20. Frietze S, Lupien M, Silver PA, Brown M. CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1. Cancer Res 2008;68:301-6.
21. Chen H, Lin RJ, Schiltz RL, et al. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 1997;90:569-80.
22. Li H, Gomes PJ, Chen JD. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci U S A 1997;94:8479-84.
23. Takeshita A, Cardona GR, Koibuchi N, Suen CS, Chin WW. TRAM-1, a novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1. J Biol Chem 1997;272:27629-34.
24. Torchia J, Rose DW, Inostroza J, et al. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 1997;387:677-84.
25. Avivar A, Garcia-Macias MC, Ascaso E, Herrera G, O'Connor JE, de Mora JF. Moderate overexpression of AIB1 triggers pre-neoplastic changes in mammary epithelium. FEBS Lett 2006;580:5222-6.
26. Tedesco D, Vesco C. MyoD activity upregulates E2F1 and enhances transcription from the cyclin E promoter in differentiating myoblasts lacking a functional retinoblastoma protein. Exp Cell Res 2001;269: 301-11.
27. Ma Y, Yuan J, Huang M, Jove R, Cress WD. Regulation of the cyclin D3 promoter by E2F1. J Biol Chem 2003;278:16770-6.
28. Ohtani K, DeGregori J, Nevins JR. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci U S A 1995;92: 12146-50.
29. 1/S-regulatory genes. Mol Cell Biol 1995;15:4215-24.
30. Stubbs MC, Strachan GD, Hall DJ. An early S phase checkpoint is regulated by the E2F1 transcription factor. Biochem Biophys Res Commun 1999;258:77-80.
31. Stender JD, Frasor J, Komm B, Chang KC, Kraus WL, Katzenellenbogen BS. Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. Mol Endocrinol 2007;21:2112-23.
32. Han S, Park K, Bae BN, et al. E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide. Breast Cancer Res Treat 2003;82:11-6.
33. 1/S transition phase in mesangial cells by E2F1. Kidney Int 1999;56:1238-41.
34. Kowalik TF, DeGregori J, Schwarz JK, Nevins JR. E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J Virol 1995;69:2491-500.
35. 1/S transition and DNA replication. Cancer Cell 2003;3:311-6.
36. Lillibridge CD, O'Connell BC. In human salivary gland cells, overexpression of E2F1 overcomes an interferon-γ- and tumor necrosis factor-α-induced growth arrest but does not result in complete mitosis. J Cell Physiol 1997;172:343-50.
37. Adams PD, Kaelin WG, Jr. The cellular effects of E2F overexpression. Curr Top Microbiol Immunol 1996;208:79-93.
38. Wang W, Dong L, Saville B, Safe S. Transcriptional activation of E2F1 gene expression by 17β-estradiol in MCF-7 cells is regulated by NFY-Sp1/estrogen receptor interactions. Mol Endocrinol 1999;13: 1373-87.
39. Pearce ST, Liu H, Jordan VC. Modulation of estrogen receptor á function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. J Biol Chem 2003;278:7630-8.
40. Klinge CM, Jernigan SC, Smith SL, Tyulmenkov VV, Kulakosky PC. Estrogen response element sequence impacts the conformation and transcriptional activity of estrogen receptor α. Mol Cell Endocrinol 2001;174:151-66.
41. Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998;95:927-37.
42. Teyssier C, Chen D, Stallcup MR. Requirement for multiple domains of the protein arginine methyltransferase CARM1 in its transcriptional coactivator function. J Biol Chem 2002;277:46066-72.